13G Filing: Partner Fund Management and Aerie Pharmaceuticals Inc (AERI)

Page 2 of 13

Page 2 of 13 – SEC Filing

CUSIP No. 00771V108 13G Page 2 of 13 Pages

1.

NAME OF REPORTING PERSON

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Partner Fund Management, L.P.

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)      ¨

(b)     x

3.

SEC USE ONLY

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

 

NUMBER
OF

SHARES

BENEFICIALLY

OWNED
BY

EACH

REPORTING

PERSON

WITH

 

5.

SOLE
VOTING POWER

0

6.

SHARED
VOTING POWER

 

2,210,020
shares

7.

SOLE
DISPOSITIVE POWER

0

8.

SHARED
DISPOSITIVE POWER

See
Row 6 above

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

See Row 6 above

10.

CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

¨

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

6.2%1

12.

TYPE OF REPORTING PERSON

IA; PN

1 The percentages reported in this Schedule 13G are based upon 35,378,682 shares of common stock outstanding
as of June 1, 2017 according to the prospectus supplement filed by the issuer with the Securities and Exchange Commission on May
30, 2017.

Follow Aerie Pharmaceuticals Inc (NASDAQ:AERI)

Page 2 of 13